Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B

Yoshihito Nagura, Kentaro Matsuura, Etsuko Iio, Koji Fujita, Takako Inoue, Akihiro Matsumoto, Eiji Tanaka, Shuhei Nishiguchi, Jong-Hon Kang, Takeshi Matsui, Masaru Enomoto, Hiroki Ikeda, Tsunamasa Watanabe, Chiaki Okuse, Masataka Tsuge, Masanori Atsukawa, Masakuni Tateyama, Hiromi Kataoka and Yasuhito Tanaka

PLOS ONE, 2022, vol. 17, issue 2, 1-13

Abstract: We examined the association between serum miRNA (-192-5p, -122-3p, -320a and -6126-5p) levels and the efficacy of pegylated interferon (Peg-IFN) monotherapy for chronic hepatitis B (CHB) patients. We enrolled 61 CHB patients treated with Peg-IFNα-2a weekly for 48 weeks, of whom 12 had a virological response (VR) and 49 did not VR (non-VR). A VR was defined as HBV DNA

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263844 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 63844&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0263844

DOI: 10.1371/journal.pone.0263844

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().